Jonathan Edelman, senior vice president of CSL’s vaccines innovation unit, said the approval “marks a significant milestone” ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive ...

Highmark expands virtual care access with Virtual Pelvic Health powered by Sword Health KOSTAIVE, the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission, represents ...

Significant research news last week included a setback for Pliant Therapeutics, when it paused a Phase IIb trial of its bexotegrast in idiopathic pulmonary fibrosis (IPP). Also, US biotech AnaptysBio ...

KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional ...

Also in Europe, officials signed off on CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine, Kostaive, for use in individuals ages 18 and older. The approval is based on results ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU. The importance of biosimilars only continues to grow ...